The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors.
The Growth Buyout team at Frazier Healthcare Partners backs successful platform companies that address key facets of the healthcare universe and brings an intensive operating approach to help those companies achieve accelerated growth. Frazier has been making Growth Buyout investments since 1993 and generally seeks thesis-driven acquisitions and recapitalizations of companies with between $5MM and $50MM of EBITDA.
The Growth Buyout team has extensive experience with all types of transactions, including complex small buyouts, recapitalizations, corporate carve-outs and consolidations of subperforming platform assets. Notable Growth Buyout companies include Bravo Health, TridentUSA, DSI Renal, and PCI, all of which have become market leaders in their sectors.
The Growth Buyout team is based in Seattle, WA, with team members also located in Los Angeles, Pittsburgh, Menlo Park, and San Diego. The investment team is augmented by an expansive group of operating partners and senior advisors, each with a distinguished track record as a successful healthcare executive.
By the numbers as of Q2 2018
- 96 acquisitions completed by portfolio companies
- 4 cross-border transactions
- $4.5B+ in debt raised for companies from banks or capital markets
- 3 corporate carve-outs in current portfolio